Trial Profile
Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2016
Price :
$35
*
At a glance
- Drugs OPC 249 (Primary)
- Indications Pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 20 Jan 2010 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 20 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2008 The expected completion date for this trial is added (Dec 2008) as reported by ClinicalTrials.gov.